| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/20/2007 | US7193064 antibody or a functional fragment thereof that recognizes a human CD40 antigen present on the surface of human B cells, dendritic cells |
| 03/20/2007 | US7192966 Pharmaceutical composition |
| 03/20/2007 | US7192949 Anticarcinogenic and antiproliferative agents |
| 03/20/2007 | US7192929 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 03/20/2007 | US7192927 An isolated BAX gene frameshift-mutation polypeptide is used to stimulate the proliferation of human T cells, T cellular immunity; for treating cancer patient; cancer vaccines |
| 03/20/2007 | US7192917 treating diseases characterized by activation of an inflammatory cytokine cascade, particularly sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an antagonist to high mobility group 1 protein |
| 03/20/2007 | US7192725 Flagellin gene, flaC of Campylobacter |
| 03/20/2007 | US7192721 Universal rapid test and method for detection of tuberculosis in multiple host species |
| 03/20/2007 | US7192718 Binds to Osteoclastogenesis Inhibitory Factor (OCIF) binding molecule (OBM) |
| 03/20/2007 | US7192717 GASP1: a follistatin domain containing protein |
| 03/20/2007 | US7192715 Diagnostics and therapy of epstein-barr virus in autoimmune disorders |
| 03/20/2007 | US7192704 Methods for detection and treatment of neural cancers |
| 03/20/2007 | US7192596 Recombinant toxin fragments |
| 03/20/2007 | US7192595 Peptide-based vaccine for influenza |
| 03/20/2007 | US7192594 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| 03/20/2007 | US7192593 Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens |
| 03/20/2007 | US7192592 administering protein comprising a first polypeptide disulfide-bonded to a second polpeptide, wherein each of said first and second polypeptides comprises amino acid residues 258 to 370 of SEQ ID NO:2 and wherein said protein is mitogenic or chemotactic for mesenchymal cells |
| 03/20/2007 | US7192590 Compounds for treatment of infectious and immune system disorders and methods for their use |
| 03/20/2007 | US7192589 Treatment of inflammatory disorders with STIgMA immunoadhesins |
| 03/20/2007 | US7192588 Stable compressed or hard tableted vaccine composition comprising at least one lyophilized antigenic component and a dissolution aid |
| 03/20/2007 | US7192586 Topical administration of an anti-PSMA antibody alone or conjugated to a cytotoxic moiety to the extracellular domain of human prostate specific membrane antigen (PSMA); anti-proliferative agents and - carcinogenic agents |
| 03/20/2007 | US7192585 Inhibiting or preventing T cell/B cell interactions associated with Crohn's disease comprising administering an amount of a monoclonal anti-CD80 antibody |
| 03/20/2007 | US7192584 Therapy of psoriasis in a human comprising administering human necrosis factor (TNF)-inhibiting amount of an anti-TNF antibody, wherein anti-TNF antibody competitively inhibits binding of TNF to monoclonal antibody cA2 |
| 03/20/2007 | US7192583 Transforming growth factor binding proteins; fusion proteins; knockout animal models; for treatment of osteoporosis/ fractures |
| 03/20/2007 | US7192582 Human monoclonal antibodies to FC alpha receptor (CD89) |
| 03/20/2007 | US7192578 By administering antiinflammatory drugs |
| 03/20/2007 | CA2256696C Modified small rna viruses |
| 03/20/2007 | CA2223080C Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2,5-anhydro-d-mannose terminal structure and conjugate vaccine thereof |
| 03/20/2007 | CA2204266C Purified papillomavirus proteins |
| 03/20/2007 | CA2002868C Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| 03/16/2007 | CA2560283A1 Antibodies as growth promoting agents |
| 03/15/2007 | WO2007030642A2 Toxin conjugated eph receptor antibodies |
| 03/15/2007 | WO2007030637A2 Hiv gp120 crystal structure and its use to identify immunogens |
| 03/15/2007 | WO2007030602A2 Treatment of b cells with il-21 and b cell activators induces granzyme b production |
| 03/15/2007 | WO2007030477A2 Solid solution perforator containing drug particle and/or drug-adsorbed particles |
| 03/15/2007 | WO2007030451A2 Antibodies as t cell receptor mimics, methods of production and uses thereof |
| 03/15/2007 | WO2007029712A1 Promoter for introducing gene into lymphocyte or blood cell and application thereof |
| 03/15/2007 | WO2007029054A1 Immunoglobulin comprising predominantly a man7glcnac2, man8glcnac2 glycoform |
| 03/15/2007 | WO2007028985A2 Adjuvanted vaccine |
| 03/15/2007 | WO2007028823A1 Pcv-2 vaccine |
| 03/15/2007 | WO2007028574A2 Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules |
| 03/15/2007 | WO2007028573A1 Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine |
| 03/15/2007 | WO2007028196A1 Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
| 03/15/2007 | WO2006136704A3 Cdna construct of salmonidae alphavirus |
| 03/15/2007 | WO2006135862A3 Immunomodulation by altering sphingosine 1-phosphate lyase (spl) activity |
| 03/15/2007 | WO2006133164A3 Anti-trkb monoclonal antibodies and uses thereof |
| 03/15/2007 | WO2006126025A3 Cytokine |
| 03/15/2007 | WO2006123230A3 Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
| 03/15/2007 | WO2006121422A3 Antibodies against clostridium difficile toxins and uses thereof |
| 03/15/2007 | WO2006114273A3 Vaccine |
| 03/15/2007 | WO2006103562A3 Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment |
| 03/15/2007 | WO2006099451A3 Novel human, feline, chicken and other animal interferons and uses thereof |
| 03/15/2007 | WO2006097689A3 Antibodies against candida antigens |
| 03/15/2007 | WO2006091666A3 Methods and compositions for treating conditions of the eye |
| 03/15/2007 | WO2006087563A3 Adjuvant composition comprising aluminium phosphate and 3d-mpl |
| 03/15/2007 | WO2006067469A3 Compositions comprising opa protein epitopes |
| 03/15/2007 | WO2006046143A3 Immunogenic bacterial vesicles with outer membrane proteins |
| 03/15/2007 | WO2005007831A3 Compositions of protein mimetics and methods of using same against hiv-1, sars-cov and the like |
| 03/15/2007 | WO2003082006A3 Methods and compositions for preventing obesity and obesity related disorders |
| 03/15/2007 | WO2003068169A3 Stabilized synthetic immunogen delivery system |
| 03/15/2007 | US20070061901 Methods to inhibit growth of prostate cancer cells |
| 03/15/2007 | US20070060540 Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
| 03/15/2007 | US20070059808 Compositions and methods for inhibiting white spot syndrome virus (wssv) infection |
| 03/15/2007 | US20070059806 Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
| 03/15/2007 | US20070059804 polynucleotides that code cysteine mutant proteins that bind to their cognate receptor or exhibit antiviral activity |
| 03/15/2007 | US20070059799 Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| 03/15/2007 | US20070059793 Nogo receptor binding protein |
| 03/15/2007 | US20070059758 Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding |
| 03/15/2007 | US20070059729 Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer |
| 03/15/2007 | US20070059681 Method for production of bioresorable microparticles, microparticles thus obtained and use thereof |
| 03/15/2007 | US20070059389 Preventives or remedies for infection, anti-endotoxin agents, vaccine adjuvants and growth promoters |
| 03/15/2007 | US20070059374 Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces |
| 03/15/2007 | US20070059336 Anti-angiogenic sustained release intraocular implants and related methods |
| 03/15/2007 | US20070059329 Unexpected surface proteins in meningococcus |
| 03/15/2007 | US20070059328 Process for manufacturing pharmaceutical composition comprises of mycobacterium w in the treatment of asthma (obstructive lung disease) |
| 03/15/2007 | US20070059327 Streptococcus equi compositions and methods of use |
| 03/15/2007 | US20070059326 Escherichia coli-derived vaccine and therapy against botulism |
| 03/15/2007 | US20070059325 Genetic vaccine against PWD circovirus |
| 03/15/2007 | US20070059324 Circovirus sequences associated with piglet weight loss disease (PWD) |
| 03/15/2007 | US20070059323 DNA composition encoding an immunogenic VEGF receptor peptide and methods of use thereof |
| 03/15/2007 | US20070059322 Episome for transfer and expression of heterologous nucleotide sequences in gram positive bacteria; genetic vaccines |
| 03/15/2007 | US20070059320 Method for ameliorating pain by modification of NMDA receptors through inhibition of Src |
| 03/15/2007 | US20070059319 Methods of screening for immuno-adjuvants and vaccines comprising anti-microtubule immuno-adjuvants |
| 03/15/2007 | US20070059318 Lipid nano particulates containing antigens as cancer vaccines |
| 03/15/2007 | US20070059316 Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted pdt agents |
| 03/15/2007 | US20070059315 Prostate stem cell antigen vaccines and uses thereof |
| 03/15/2007 | US20070059314 Novel anti-angiogenic agent and its use in particular within the framework of the treatment of cancer |
| 03/15/2007 | US20070059313 Homogeneous preparations of il-28 and il-29 |
| 03/15/2007 | US20070059312 Anti-vegf antibodies |
| 03/15/2007 | US20070059311 Regulation of the hedgehog signaling pathway and uses thereof |
| 03/15/2007 | US20070059310 Therapeutic combination compositions and methods of using same |
| 03/15/2007 | US20070059309 Culturing a host cell transformed with a nucleic acid encoding murine anti-human IFN- alpha monoclonal antibody 9F3; culture product neutralizes all seven of recombinant human IFN- alpha subtypes tested; diseases involving cell overexpression; autoimmune diseases; antidiabetic agents; lupus (SLE) |
| 03/15/2007 | US20070059308 efficient, high throughput screening of antibody libraries against proteins targets; for screening a diverse antibody library for antibodies that bind to a membrane protein such as a chemokine receptor in yeast |
| 03/15/2007 | US20070059307 Biological products |
| 03/15/2007 | US20070059306 Using tetraspanin specific immunoglobulin for use in treatment of cell proliferative disorders; small, modular immunopharmaceuticals |
| 03/15/2007 | US20070059305 Neutralizing human anti-IGFR antibody |
| 03/15/2007 | US20070059304 Anti-TrkB monoclonal antibodies and uses thereof |
| 03/15/2007 | US20070059303 monoclonal antibody for prevention and treatment of allergies, asthma, crohn's and lymes disease, arthritis, diabetes, glomerularnephritis, vision defects, skin disorders, sarcoidosis and viral diseases |
| 03/15/2007 | US20070059302 Endothelial growth factor specific immunoglobulin for use in treatment and prevention of diabetic retinopathy and neovascular vision defects |
| 03/15/2007 | US20070059301 Modified antibody fragments |